RecruitingPhase 4NCT03384563

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane


Sponsor

Baylor College of Medicine

Enrollment

180 participants

Start Date

Feb 18, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.


Eligibility

Min Age: 1 MonthMax Age: 36 Months

Inclusion Criteria1

  • All patients age 1 month- 3 years presenting for surgery.

Exclusion Criteria14

  • Interstitial lung disease, chest wall disease, or bronchospastic disease with no flare-ups in the past 2 weeks of presentation
  • History of difficult intubation or ventilation
  • Airway malformation
  • Congenital heart disease
  • Cardiac arrhythmias
  • Central nervous system disease, including developmental delay, cerebral palsy, or seizure disorder
  • History of or family history of malignant hyperthermia
  • Electrolyte disorders
  • Gastrointestinal disease
  • Hepatic dysfunction
  • Renal dysfunction
  • Metabolic disease, such as diabetes
  • Obesity, defined as a body mass index greater than the 95% percentile for age
  • Preterm infant (less than 37 weeks gestational age) 15. Use of any medications (anticonvulsants, opioids, benzodiazepines, antibiotics, antihistamines drugs that induce hepatic enzymes) that may affect MAC.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexmedetomidine

Dexmedetomidine 9 arms


Locations(1)

Texas Children's Hospital

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03384563


Related Trials